Archive for category: Special Report

Why Life Sciences Manufacturers Should Not Read the Oversupply Headlines as Their Story

The cold storage industry is working through an oversupply. After a speculative construction boom that added roughly 14.5% capacity between 2021 and 2025, the sector is now absorbing an estimated 10% oversupply, and capacity growth is decelerating sharply as developers and lenders pull back from new projects. Read on its own, that data suggests temperature-controlled storage is easy to find and getting cheaper.

For a life sciences manufacturer that needs FDA-registered, cGMP-compliant storage for raw materials, work-in-process, or finished product, that reading is misleading. The cold storage oversupply is concentrated in general-purpose refrigerated space, much of it built for food and bulk perishables. Pharmaceutical-grade storage is a different market with different economics, and within the broader cold storage sector, pharmaceutical cold chain is consistently identified as the fastest-growing demand segment, not an oversupplied one.

A manufacturer who reads “cold storage is oversupplied” and assumes validated pharmaceutical capacity will be easy to secure is reading the wrong segment of the market. General refrigerated space and cGMP-compliant pharmaceutical storage are not interchangeable, and the forces loosening one are not loosening the other.

Two Markets That Get Reported as One

Cold storage tends to be discussed as a single category in industry coverage and real estate reporting. In practice, it splits into segments with very different supply and demand dynamics, and the gap between them matters enormously for a life sciences manufacturer trying to plan capacity.

The oversupply that dominates recent headlines is concentrated in general-purpose cold storage: the large refrigerated and frozen warehouses that serve food processing, grocery distribution, and bulk perishables. That segment saw heavy speculative construction during the pandemic years, and it is now working through the resulting excess. Frozen storage alone accounts for roughly half of total cold storage demand, and much of the new speculative capacity was built for exactly that kind of high-volume, food-oriented use.

Pharmaceutical-grade storage is a fundamentally different product. It requires FDA registration, cGMP-compliant quality systems, validated temperature zones, continuous monitoring, audit-ready documentation, and often security certifications like CTPAT. A food-grade frozen warehouse with empty pallet positions does not meet those requirements, and it cannot be casually converted to meet them. The oversupply in one segment does very little to ease capacity in the other.

Why Pharmaceutical Storage Demand Keeps Rising

While general cold storage absorbs its oversupply, the demand drivers for pharmaceutical-grade storage continue to strengthen. Several forces are converging:

Biologics and Specialty Medicine Pipeline

The pharmaceutical pipeline has shifted decisively toward biologics, cell and gene therapies, and other specialty medicines that require refrigerated or frozen storage throughout the supply chain. The gene, cell, and RNA therapy pipeline reached thousands of therapies in development as of 2025, and specialty medicines are projected to account for a growing majority of new drug launches. Nearly all of these products require validated cold chain storage that general refrigerated space cannot provide.

The GLP-1 Surge

The explosive growth of GLP-1 medications for diabetes and weight management has created substantial new demand for pharmaceutical-grade refrigerated storage and handling. These are temperature-sensitive biologics produced and distributed at enormous scale, and they require cold chain infrastructure that meets pharmaceutical, not food-grade, standards.

Reshoring and Domestic Manufacturing

The wave of U.S. pharmaceutical manufacturing investment now underway is generating new domestic demand for validated raw-material and finished-product storage. As more pharmaceutical production happens on U.S. soil, the need for compliant warehousing to stage imported inputs and hold finished product grows alongside it.

Supply Resilience and Safety Stock

The supply chain disruptions of recent years have made pharmaceutical companies more willing to hold safety stock of critical products and inputs. That strategic inventory requires validated storage capacity, adding to demand that is structural rather than temporary.

The Risk of Misreading the Market

The practical danger for a life sciences manufacturer is straightforward. A company that reads the cold storage oversupply headlines and concludes that validated pharmaceutical storage will be readily available, and cheap, when it needs it may delay a capacity decision that should be made proactively. Then, when a production ramp, a commercial launch, or an inventory surge creates an urgent need, the specific validated, FDA-registered, cGMP-compliant space required may not be available in the right location on the timeline the business needs.

Validated pharmaceutical storage cannot be stood up overnight. Whether a manufacturer builds it internally or secures it through a qualified partner, the process of qualifying space, validating temperature zones, and establishing compliant quality systems takes time. A general-purpose cold storage glut provides no cushion against that reality, because the empty space in the glut is the wrong kind of space.

The headline that matters for a life sciences manufacturer is not “cold storage is oversupplied.” It is “pharmaceutical-grade cold chain is the fastest-growing demand segment.” Those two facts are both true at the same time, and only the second one describes the market a manufacturer actually operates in.

What Life Sciences Manufacturers Should Do

Given the gap between the general cold storage picture and the pharmaceutical-grade reality, a few practical priorities follow for manufacturers planning their storage strategy:

• Plan capacity against pharmaceutical-grade supply, not general cold storage headlines. The oversupply in food-grade space is irrelevant to your validated storage needs
• Decide proactively, not reactively. Secure validated storage capacity before a production ramp or launch forces an urgent decision, when options are fewer and timelines are tighter
• Evaluate qualified partners early. A relationship with an FDA-registered, cGMP-compliant storage partner can provide capacity faster than building internally, but the qualification process still takes time to do properly
• Weigh location alongside capacity. Validated space in the wrong region adds transit time and freight cost. Proximity to your manufacturing and distribution footprint matters
• Confirm the specifics, not just the label. “Temperature-controlled” is not the same as validated cGMP storage. Confirm FDA registration, validated zones, monitoring, and documentation

How Euro-American Worldwide Logistics Fits

Euro-American Worldwide Logistics operates a 45,000 square foot FDA-registered, cGMP-compliant facility in Worcester, Massachusetts, with 25,000 square feet of dual temperature-controlled refrigeration supporting validated 2 to 8 degrees C and 15 to 25 degrees C storage. This is pharmaceutical-grade storage built and maintained for FDA-regulated products, not general cold storage repurposed for pharmaceutical use.

For life sciences manufacturers in the Northeast evaluating storage capacity, whether for raw material staging, safety stock, overflow, or finished-product distribution, we provide validated storage with continuous monitoring, ISO-9001 certified quality systems, CTPAT-certified security, and the integrated customs brokerage and freight forwarding that support internationally sourced materials. And we are positioned centrally in the Massachusetts life sciences corridor, close to the manufacturers and research institutions we serve.

If you are planning your pharmaceutical storage strategy and want to talk through validated capacity that fits your requirements and timeline, contact our team today.

Sources include Westside Construction Group analysis of the 2026 cold storage construction cycle; Future Market Insights and DataM Intelligence cold chain market data; GCCA Cold Facts 2026 outlook; and American Society of Gene & Cell Therapy pipeline data. Market figures reflect the cited sources and span differing methodologies and time horizons.

The headlines are striking. Reuters reported in August 2026 that major global pharmaceutical companies have announced more than $500 billion in combined U.S. manufacturing, research, and supply chain investment commitments. The list of companies is a who’s who of the industry: Pfizer, Eli Lilly, Johnson & Johnson, Roche, AstraZeneca, Novartis, Merck, Amgen, AbbVie, Gilead, Sanofi, and others. At the same time, FDA is actively promoting domestic manufacturing capacity through programs such as FDA PreCheck, designed to streamline the regulatory readiness of new U.S. drug manufacturing facilities.

It is tempting to read this as a simple story: pharmaceutical manufacturing is coming back to America, and international logistics matters less as a result. That reading is wrong, and for any company whose supply chain touches pharmaceutical manufacturing, understanding why it is wrong is worth some attention.

A few important caveats about the headline number itself. The $500 billion figure spans very different time horizons, and should not be read as $500 billion of immediate construction. Tariff exposure is one factor driving these commitments, alongside supply security, market access, pricing agreements, and broader manufacturing strategy. And critically, building a pharmaceutical plant in the United States does not make that plant independent of international supply chains. In many cases, it creates entirely new international logistics demand.

Reshoring does not eliminate international logistics. It changes the logistics. A new U.S. pharmaceutical plant can still depend heavily on imported ingredients, equipment, and materials, and it generates new domestic warehousing and distribution requirements that did not exist before.

1. Finished-Drug Imports Versus Raw-Material Imports

The reshoring narrative focuses on finished drug manufacturing: the plants that produce the tablets, vials, and injectables that reach patients. Moving that final production step to the United States does reduce finished drug imports over time. But finished drug production is the last stage of a long supply chain, and the stages before it remain heavily international.

A U.S. plant that manufactures a finished biologic or small molecule drug still needs active pharmaceutical ingredients, excipients, and packaging to do so. If those inputs are imported, and for most U.S. pharmaceutical production today they substantially are, then the reshoring of finished manufacturing has shifted the composition of pharmaceutical imports rather than eliminating them. Fewer finished drugs cross the border. More raw materials and components do.

2. APIs and Excipient Sourcing

The active pharmaceutical ingredient is the heart of any drug, and API manufacturing is one of the most globally concentrated segments of the entire pharmaceutical supply chain. A large share of global API production, and an even larger share of the key starting materials that feed API synthesis, is concentrated in China and India. That concentration does not disappear because a finished drug plant opens in Virginia or Massachusetts.

In fact, a new domestic finished-drug facility often increases API import demand at its point of entry, because that facility needs a reliable, compliant, well-documented inbound flow of API to operate. The same applies to excipients, the binders, fillers, stabilizers, and delivery agents that make up the non-active portion of a finished drug. Many specialized excipients are produced by a small number of international suppliers, and a U.S. plant depends on importing them regardless of where the final drug is made.

For the logistics function, this means the reshoring trend is generating demand for exactly the capabilities that support compliant pharmaceutical importing: customs brokerage, FDA-coordinated entry, temperature-controlled handling for sensitive inputs, and validated storage of incoming raw materials.

3. Equipment and Spare-Parts Logistics

Building a pharmaceutical manufacturing facility requires pharmaceutical manufacturing equipment, and much of the world’s specialized bioprocessing and fill-finish equipment is built outside the United States. Bioreactors, chromatography systems, isolators, fill-finish lines, and process analytical technology are frequently manufactured in Europe and elsewhere, then imported, installed, and qualified in the new U.S. facility.

This creates a distinct and time-sensitive logistics requirement during the construction and commissioning phase of every reshoring project. High-value, often oversized, and sometimes sensitive equipment must be imported, cleared through customs, and delivered on a schedule that aligns with facility construction milestones. A customs delay on a critical piece of equipment can push back a facility qualification timeline by weeks.

The requirement does not end when the facility opens. Imported manufacturing equipment needs imported spare parts, and it needs them on demand. A production line down for want of a replacement component sourced from an overseas manufacturer is an expensive problem. Reliable, fast import handling for spare parts is an ongoing logistics need that begins the day the plant becomes operational and continues for the life of the equipment.

4. GMP Raw-Material Warehousing

A domestic pharmaceutical plant that depends on imported APIs, excipients, and components needs somewhere to store those materials under compliant conditions. Raw materials for pharmaceutical manufacturing frequently require validated temperature control, controlled humidity, segregation, and full chain-of-custody documentation, the same cGMP standards that apply to finished product.

Manufacturers often do not want to build all of that raw-material storage capacity inside the manufacturing facility itself, where floor space is expensive and dedicated to production. Staging imported raw materials at a nearby GMP-compliant warehouse, then feeding them into the plant on a just-in-time or scheduled basis, is an efficient model that preserves manufacturing floor space and provides an inventory buffer against supply disruptions. That is a direct, growing demand for exactly the kind of validated GMP warehousing that supports a manufacturing operation.

5. Supplier Diversification

The same forces driving pharmaceutical reshoring, supply security concerns, tariff exposure, and geopolitical risk, are also driving supplier diversification for the inputs that reshored plants depend on. A manufacturer building a new U.S. facility to reduce its dependence on foreign finished-drug production is often simultaneously working to diversify the sources of its APIs and raw materials, moving away from single-country concentration.

Supplier diversification multiplies logistics complexity. Sourcing an API from three countries instead of one means three sets of customs entries, three country-of-origin determinations, three sets of supplier documentation, and three inbound freight relationships to manage. The reshoring of finished manufacturing and the diversification of upstream sourcing are happening together, and both increase, rather than decrease, the demand for sophisticated customs and logistics expertise.

6. Safety-Stock Strategy

One of the central motivations behind pharmaceutical reshoring is supply security, the desire to avoid the shortages and disruptions that occur when a critical medicine depends on a fragile, distant, single-source supply chain. But supply security is not achieved by domestic manufacturing alone. It is achieved by holding appropriate safety stock of critical inputs and finished product.

A manufacturer serious about supply resilience will carry buffer inventory of imported APIs and critical raw materials, precisely so that a disruption in international supply does not halt domestic production. That safety stock has to be stored somewhere, under compliant conditions, with accurate inventory management and full documentation. The reshoring trend, properly understood, increases the demand for validated warehousing capacity to hold the strategic inventory that makes domestic production resilient.

7. Customs Planning for Manufacturing Inputs

a company imports finished drugs, its customs activity is relatively straightforward: a defined set of finished products, classified and entered on a predictable basis. When that same company shifts to domestic manufacturing that relies on imported inputs, its customs profile becomes more complex, not less.

Now the company is importing APIs, excipients, packaging components, equipment, and spare parts, each with its own HTS classification, its own regulatory requirements, and its own entry considerations. Some inputs may face Section 232 pharmaceutical tariffs depending on classification and origin. Some may qualify for exemptions. Country-of-origin determinations become more numerous and more consequential. The customs planning required to support a domestic manufacturing operation is substantially more involved than the customs planning required to simply import a finished product.

This is a critical and often underappreciated point. Reshoring finished manufacturing does not simplify a company’s customs footprint. It transforms it into a more complex, higher-volume, more varied set of import activities that require ongoing customs brokerage expertise to manage compliantly.

8. Distribution Requirements Once Domestic Production Begins

Finally, a domestic pharmaceutical plant does not just receive inputs. It produces finished product that has to be distributed. Once a U.S. facility begins commercial production, it generates demand for finished-product warehousing, temperature-controlled distribution, order fulfillment, and final-mile delivery, all under cGMP conditions and all within the United States.

This is domestic logistics demand that did not exist when the product was manufactured abroad and imported in finished form. The reshoring of manufacturing creates a new domestic distribution requirement at the output end of the plant, just as it creates new import requirements at the input end. Both are logistics demand, and both are growing as the reshoring investments move from announcement to operation.

The Bigger Picture: A Different Logistics Map, Not a Smaller One

The table below summarizes the categories of international and domestic logistics demand that pharmaceutical reshoring generates, rather than eliminates.

The reshoring of pharmaceutical manufacturing is real, and it is significant. But it is not the end of pharmaceutical logistics complexity. It is a redrawing of the map. The flows change. Finished-drug imports decline over time, while imports of APIs, excipients, equipment, and spare parts rise. New domestic warehousing and distribution requirements emerge. Customs activity becomes more complex, not less. Supplier diversification multiplies the number of relationships to manage.

For pharmaceutical manufacturers, the practical implication is that a domestic manufacturing strategy needs a logistics strategy to match, one that accounts for compliant importing of manufacturing inputs, GMP-compliant raw-material and finished-product warehousing, sophisticated customs planning, and domestic distribution capability.

How Euro-American Worldwide Logistics Supports Reshored Manufacturing

Euro-American Worldwide Logistics is built for exactly the logistics profile that pharmaceutical reshoring creates. Our integrated platform combines licensed U.S. Customs Brokerage, international freight forwarding, and cGMP-compliant warehousing under one roof in Worcester, Massachusetts, at the center of one of the most active life sciences manufacturing regions in the country.

For a manufacturer importing APIs, excipients, packaging, equipment, or spare parts to support U.S. production, our customs brokerage team manages the classification, entry, and compliance requirements, while our validated cGMP warehouse provides the temperature-controlled staging and safety-stock storage that a resilient manufacturing operation depends on. For finished product coming off a domestic line, we provide the compliant warehousing and distribution to move it to market.

If your organization is building or expanding U.S. pharmaceutical manufacturing capacity and wants a logistics partner who understands that reshoring changes logistics rather than eliminating it, contact our team today.

Sources include Reuters reporting on pharmaceutical U.S. investment commitments (August 2026); company investment announcements from AstraZeneca, Eli Lilly, Johnson & Johnson, Pfizer, Merck, and others; and FDA materials on the PreCheck program for domestic manufacturing facilities. Investment figures span multiple time horizons and should not be read as immediate construction spending.

On July 13, 2026, FDA updated the import alert covering drugs and medical devices from firms without valid registration and listing. FDA’s import alert database is updated in real time, and products identified under this alert may be subject to detention without physical examination, meaning the shipment is held automatically at the port of entry without FDA needing to test or physically inspect it first.

An update to this alert does not necessarily represent a new agency-wide policy. Updates of this kind routinely add or remove individual firms or products and revise alert information as FDA’s records change. But the update is a useful prompt to revisit a phrase that appears constantly in supplier qualification conversations and rarely gets defined precisely: FDA registered.

For pharmaceutical, biotech, and medical device importers, that phrase is doing more work in casual conversation than it can actually support as a compliance verification. This article breaks down what FDA registration actually confirms, what it does not, and what a complete import readiness verification should include.

Why This Matters Operationally: A freight forwarder, customs broker, or GMP warehouse cannot correct a deficient establishment registration after the shipment reaches the border. At that point, the logistics problem becomes detention, controlled storage, demurrage, and the management of a temperature-sensitive product’s remaining shelf life while the underlying compliance issue is resolved.

Six Distinct Compliance Concepts Hiding Behind One Phrase

When a supplier, a sales contact, or a commercial invoice describes a product as FDA registered, that statement can be referring to any one of several distinct regulatory concepts, and importers frequently assume it covers more ground than it does. The table below separates these concepts and shows why confirming one does not confirm the others.

Establishment registration is a precondition to admissibility. It is not, by itself, evidence that a specific shipment is compliant, correctly listed, properly authorized, free of import alert exposure, or accurately declared on the entry.

Why the July 13 Update Is a Useful Prompt

Import alerts covering unregistered or unlisted firms exist precisely because registration and listing status can change, and because FDA’s compliance database reflects real-time additions and removals. A manufacturer that was properly registered when a supplier relationship began can lose that status. A product that was correctly listed can fall out of compliance if the establishment’s registration lapses or the listing is not maintained.

This means supplier verification is not a one-time event that happens during initial qualification. It is an ongoing verification that should be repeated at intervals, and certainly before any shipment moves, particularly for suppliers or products that have not shipped recently.

A commercial invoice or a supplier’s written assurance that a facility is FDA registered reflects the supplier’s understanding of their own status. It does not reflect a current, independent check against FDA’s own records at the time of shipment.

What a Complete Import Readiness Verification Includes

Before a regulated shipment departs, importers should independently verify the following, rather than relying on supplier representations alone:

1. Verify the actual manufacturing establishment, not just the name on the commercial invoice.
2. Confirm the establishment’s current registration status directly against FDA records.
3. Confirm the exact product listing tied to that registered establishment.
4. Confirm the party identified on FDA entry data matches the actual manufacturer.
5. Check whether the manufacturer or the specific product is implicated by an active import alert.

Each of these checks is available through FDA’s own public databases and systems, and a licensed customs broker with pharmaceutical and device experience should be conducting this verification as a routine part of pre-shipment compliance review, not as a special request reserved for higher-risk suppliers.

Why the Party on FDA Entry Data Matters

One verification step deserves particular attention because it is easy to overlook. The entity identified on the electronic entry data submitted to FDA through CBP’s Automated Commercial Environment must correctly identify the actual manufacturing establishment, using that establishment’s correct registration number. If the wrong establishment is identified, whether due to a data entry error, an outdated record, or confusion between a manufacturer and a distributor or trading company, the entry itself can be flagged for review even when the actual product and actual manufacturer are both properly registered and compliant.

This is a documentary error, not a product quality issue, and it illustrates why establishment registration status alone is an incomplete check. A product can come from a fully compliant, registered manufacturer and still be detained because the entry data submitted at the border does not correctly reflect that fact.

What Happens When Verification Is Skipped

When a registration or listing deficiency is discovered only after a shipment reaches a U.S. port, the available remedies are limited and none of them are fast. The importer may need to demonstrate compliance after the fact, which can require documentation from the foreign establishment that takes time to assemble. The product sits in detention, or in controlled storage if the importer can arrange it, while the issue is resolved. Demurrage and storage costs accrue. For a temperature-sensitive product, every day in detention consumes shelf life that cannot be recovered.

None of this can be fixed by the logistics function alone. A freight forwarder can expedite transportation. A customs broker can file an accurate entry. A GMP warehouse can hold a detained product under validated conditions while the issue is worked through. None of them can retroactively create a valid establishment registration or product listing that did not exist at the time of shipment. The verification has to happen before the product leaves the origin country, not after it arrives.

How Euro-American Worldwide Logistics Supports Supplier Verification

Euro-American Worldwide Logistics’ licensed U.S. Customs Brokerage conducts establishment registration and product listing verification as a standard part of pre-shipment compliance review for pharmaceutical, biologic, and medical device clients. Our team checks the manufacturing establishment identified on shipping documentation against FDA’s registration and listing records, confirms the product is correctly listed, and reviews current import alert status before a shipment moves, not after it is held at the port.

For clients working with new suppliers, or reviewing an existing supplier relationship after a period without shipments, we can perform this verification as part of supplier qualification, well before the first commercial shipment is scheduled.

If you would like to review your current supplier verification practices or have a specific shipment you want checked before it departs, contact our team today.

This article references FDA’s import alert publication record and the July 13, 2026 update to the alert covering unregistered or unlisted drug and device firms. Import alert status should be verified directly against FDA’s current records before shipment.

On July 15, 2026, the Office of the U.S. Trade Representative issued its final Section 301 action on Brazil. The action imposes an additional 25% duty on covered Brazilian origin goods entered for consumption, or withdrawn from warehouse for consumption, at or after 12:01 a.m. Eastern time on July 22, 2026. Certain products are exempt from the additional duty.

For pharmaceutical, biotech, and medical product importers with any exposure to Brazilian sourcing, this is not a straightforward yes or no situation. The tariff applies to some Brazilian goods and not others, the exemption list is specific rather than blanket, and timing around the July 22 effective date can change how a given shipment is treated. This guide walks through what importers need to verify before assuming they know how a Brazilian shipment will be treated.

The Core Mistake to Avoid: A shipper cannot safely conclude that all Brazilian pharmaceutical products are exempt, or that every shipment from Brazil now carries an additional 25% duty. Both statements are too broad. Coverage depends on the specific HTS provision, and for certain chemicals, on their pharmaceutical application.

1. Why Origin and Shipping Country Are Not Always the Same

Several structural factors have made India the dominant beneficiary of pharmaceutical sourcing diversification away from China:

The Section 301 action applies based on the customs country of origin of the goods, not the country from which the shipment was sent. A product manufactured in a third country and merely transshipped through Brazil does not become subject to this tariff by virtue of the shipping route. Conversely, a product genuinely manufactured or substantially transformed in Brazil is covered regardless of where it is shipped from.

Importers should confirm country of origin through the same substantial transformation analysis CBP applies elsewhere. Country of origin marking on the product and commercial invoice description are starting points, but the underlying manufacturing history is what actually controls.

The first verification step is not what the invoice says. It is where the actual manufacturing or substantial transformation took place.

2. How Chapter 99 Classifications Work With the Ordinary HTS Code

Section 301 tariffs are implemented through a secondary classification system. The product retains its ordinary Harmonized Tariff Schedule classification, the code that determines the base duty rate and regulatory treatment, and a Chapter 99 provision is added to the entry to reflect the additional Section 301 duty.

This means an importer needs two pieces of information for every affected shipment: the standard HTS classification for the product itself, and the applicable Chapter 99 secondary classification that reflects the Brazil action. Filing an entry with only the primary HTS code, without evaluating whether a Chapter 99 provision applies, risks an inaccurate entry regardless of whether the omission increases or decreases the duty paid.

3. Pharmaceutical Exemptions Versus Blanket Industry Exemptions

USTR expanded the final exemption list to include additional pharmaceuticals and pharmaceutical ingredients. This is a meaningful update for life sciences importers, but it should not be read as a general healthcare exemption.

The exemption operates at the level of the specific HTS provision. A product classified under an HTS code that appears on the exemption annex is excluded from the additional duty. A product that is pharmaceutical in a general commercial sense, but whose HTS classification does not appear on the annex, is not automatically covered simply because it is used in a healthcare context.

Practically, this means every product in a Brazilian pharmaceutical or medical device supply chain needs to be checked individually against the exemption annex by its specific HTS number. Assuming coverage because a related product, or a product in the same general category, is exempt is a common and avoidable error.

4. Why Intended Use May Matter for Chemical Ingredients

For certain chemical products, exemption eligibility depends not only on the HTS classification but on the chemical’s actual pharmaceutical application. A chemical compound that has both pharmaceutical and non-pharmaceutical industrial uses may be classified under a provision where exemption coverage is conditioned on the specific end use of the imported merchandise.

This creates a documentation obligation that goes beyond the customs entry itself. Importers relying on a pharmaceutical use exemption for this category of chemical inputs should be prepared to demonstrate that the specific shipment in question is, in fact, being imported for pharmaceutical application, not simply that the chemical is capable of pharmaceutical use in general.

5. Treatment of In Transit, Bonded, and Foreign Trade Zone Merchandise

The USTR notice includes a limited in transit provision for qualifying goods. Goods loaded for shipment before July 22, 2026 and entered before July 29, 2026 may qualify for treatment under this provision, avoiding the additional duty despite entering after the effective date. Importers with shipments currently in transit from Brazil should confirm loading dates and expected entry dates against this window immediately.

Goods subject to the tariff that are admitted to a U.S. foreign trade zone generally must enter under privileged foreign status, unless the goods are eligible for domestic status. This status election has consequences for how and when duty is ultimately assessed, and importers using FTZ warehousing for Brazilian origin product should confirm the correct status designation with their customs broker before the July 22 effective date.

The practical point for anyone managing Brazilian origin shipments right now: entry timing matters as much as the underlying product. A shipment arriving at a U.S. port near July 22 could receive materially different tariff treatment depending on precisely when it is entered, or when it is withdrawn from a bonded warehouse, not simply on when it left Brazil.

6. Documents Importers Should Retain to Support Exemption Claims

For any Brazilian origin product claimed as exempt, particularly pharmaceutical products and chemical ingredients where end use matters, importers should maintain documentation sufficient to support that claim in the event of a CBP request for information or an audit. Relevant records include:

• Certificates of analysis or product specification sheets confirming the product’s chemical identity and classification
• Purchase orders and commercial invoices that clearly describe the pharmaceutical application or end use of the shipment
• Manufacturing and substantial transformation records supporting the claimed country of origin
• Correspondence with the supplier confirming the intended use of chemical inputs where end use affects exemption eligibility
• Bills of lading and loading documentation for any shipment relying on the in transit provision

7. When to Request a Binding Classification Ruling

For products where the HTS classification is genuinely unclear, or where the exemption annex language does not map cleanly onto the specific product at issue, a binding ruling request to CBP provides a legally authoritative determination. This is worth pursuing for high volume products, high value shipments, or product lines where the classification question will recur across many future entries.

A binding ruling takes time to obtain and is not a solution for a shipment already in transit before July 22. But for importers with an ongoing Brazilian supply relationship, requesting rulings now on the products where classification is genuinely ambiguous protects against inconsistent treatment across future entries and reduces audit exposure.

Immediate Action Checklist

For any importer with current or planned Brazilian origin shipments, the following steps should be completed before July 22, 2026 wherever possible, and immediately thereafter for any shipment already in transit.

1. Confirm the product’s HTS classification.
2. Confirm that Brazil is the customs country of origin, not simply the country of shipment.
3. Identify the applicable Chapter 99 secondary classification.
4. Check whether the exact HTS provision appears in an exemption annex.
5. Preserve documentation supporting pharmaceutical end use where relevant.
6. Review goods already in transit, in bonded warehouses, or in foreign trade zones.
7. Recalculate landed cost before authorizing new shipments.

How Euro-American Worldwide Logistics Supports Brazil Tariff Compliance

Euro-American Worldwide Logistics operates a licensed in-house U.S. Customs Brokerage with specific expertise in pharmaceutical and medical product classification. Our brokerage team can review your Brazilian origin product portfolio against the Section 301 action and the exemption annexes, confirm the applicable Chapter 99 provisions, and assess whether shipments currently in transit qualify for relief under the in transit provision.

For life sciences importers relying on the pharmaceutical exemption for chemical ingredients with dual use applications, we can help establish the documentation practices needed to support that position if CBP requests evidence of end use.

If you have Brazilian origin shipments affected by this action, particularly any currently in transit or held in a bonded warehouse or foreign trade zone, contact our team today.

This article reflects the USTR Federal Register notice issued July 15, 2026. Tariff treatment for specific products should be confirmed with a licensed customs broker before entry.

Pharmaceutical, biotech, and medical device manufacturers all reach the same operational moment. Inventory volumes have grown. A commercial launch is approaching. A new supplier has been qualified. An existing facility is running at capacity. The question becomes whether to build, expand, or outsource the storage and materials management infrastructure your supply chain requires.

The default assumption has historically been to expand internally. But for many life sciences manufacturers, that assumption no longer holds up under scrutiny. The capital cost, time to operational readiness, and ongoing regulatory burden of in-house GMP storage have risen significantly. At the same time, the quality and capability of qualified third-party GMP storage partners has matured to the point where outsourcing is no longer a contingency. It is a strategic option that deserves serious consideration.

This article walks through the strategic case for outsourced GMP storage. It covers the cost and risk picture honestly, identifies what to look for in a storage partner, and explains where outsourcing fits in different life sciences manufacturing scenarios.

The Strategic Question Most Manufacturers Get Wrong

When manufacturers reach the storage decision point, they often frame it as a real estate question. How much square footage do we need? Where should we build? What does construction cost? Those are necessary questions, but they are not the right starting questions.

The strategic question is different: what is the highest and best use of our capital and our management attention? For a pharmaceutical or biotech company, the answer is almost always manufacturing, research, regulatory affairs, and commercialization. Logistics infrastructure is necessary, but it is not where competitive advantage is built.

Companies that invest capital in building or expanding their own GMP storage facilities are making a specific bet: that they can operate GMP warehousing more efficiently than a specialized third-party partner whose core competency is precisely that. For most manufacturers, the data suggests this bet is hard to win.

The right question is not whether you can build GMP storage. You almost certainly can. The right question is whether building it produces better outcomes than outsourcing it. For most life sciences manufacturers, it does not.

Build vs. Outsource: A Side-by-Side Look

The capital cost of a validated cGMP storage facility, including building, qualification, validation, equipment, and initial operating costs, typically runs between $20 million and $100 million depending on size, temperature zones, and security infrastructure. The timeline from groundbreaking to FDA-registered operational status is generally 18 to 36 months. Both figures are before the ongoing operational cost of staffing, maintenance, regulatory compliance, and equipment lifecycle replacement.

Outsourcing to a qualified GMP storage partner produces immediate operational capacity at a fraction of the capital outlay, with the regulatory burden carried by a partner whose core business is maintaining that standing. For most life sciences manufacturers, the cost-benefit analysis does not produce a close call.

When Outsourcing Makes Particular Sense

1. Approaching Commercial Launch

Companies moving from clinical-stage operations to commercial scale face a sudden expansion in storage requirements. Finished commercial inventory, expanded raw material stockpiles, and distribution-ready packaging all demand validated storage in volumes the company has not previously needed. Building internal capacity to support the launch is a significant capital commitment made during the most operationally intense period of a product’s lifecycle. Outsourcing the storage infrastructure removes that distraction and provides immediate commercial-scale capacity.

2. Raw Material and API Storage for Just-in-Time Manufacturing

Manufacturers operating lean production models depend on reliable just-in-time delivery of raw materials, APIs, and excipients. Buffering that supply with on-site storage means tying up working capital and floor space in inventory. Staging materials at a qualified GMP storage partner located near the manufacturing site preserves the just-in-time model while providing the inventory buffer that supply chain disruptions can demand.

3. Supplier Qualification and Onboarding

When manufacturers qualify new suppliers, particularly internationally sourced suppliers, the inbound logistics challenge is meaningful. Integrated customs brokerage, validated receiving inspection, and chain-of-custody documentation are all required. An outsourced GMP storage partner with in-house customs brokerage capacity provides these functions as an integrated service, simplifying the supplier qualification process.

4. Geographic Expansion

Manufacturers entering new geographic markets often need storage capacity in the new region before sales volume justifies a permanent facility there. Partnering with a regional GMP storage provider offers immediate geographic presence without the long-term real estate and staffing commitment.

5. Overflow and Contingency Capacity

Even manufacturers with internal GMP storage face periods when capacity is constrained, whether by inventory surge, equipment downtime, or unexpected demand. A standing relationship with a qualified GMP storage partner provides surge capacity that does not require permanent capital investment.

What to Look for in a GMP Storage Partner

The quality and capability of GMP storage providers varies meaningfully. Not every facility marketed as cGMP-compliant carries the regulatory infrastructure, validation, and operational discipline that life sciences manufacturers require. The criteria below should be the baseline of any provider evaluation:

Beyond the baseline criteria, the most important factors are operational fit and integration capability. Does the partner’s quality system integrate with yours? Can the partner support the documentation requirements your QA team needs for FDA audit response? Can the partner manage international receiving and customs clearance without creating handoff gaps? These are the questions that distinguish a transactional storage vendor from a strategic logistics partner.

Addressing Common Concerns About Outsourcing

“How Will We Maintain Control Over Inventory?”

Direct physical possession is not the same as control. Manufacturers who outsource GMP storage to a qualified partner with integrated warehouse management systems maintain real-time visibility into every carton in storage, complete chain-of-custody documentation, and audit-ready records. The partner’s quality agreement defines the operational standards. The manufacturer retains full ownership of the inventory and full access to the documentation.

“Is There a Regulatory Risk?”

Outsourcing GMP storage to a qualified partner transfers operational responsibility for daily warehouse operations, but does not transfer regulatory responsibility for the product. The manufacturer remains accountable to FDA for product integrity. The right partner reduces regulatory risk by providing a higher level of compliance infrastructure than most manufacturers can maintain internally, supported by a documented quality system, regular FDA inspections, and ongoing certification audits.

“Any Loss of Operational Flexibility?”

The opposite is generally true. Outsourced storage scales up or down with actual inventory needs without capital commitments. Internal facilities have fixed footprints that are expensive to expand and costly to operate at low utilization. Outsourced storage provides flexibility that internal facilities do not.

“Can Custom Requirements Be Accommodated?”

Qualified GMP storage partners regularly support specialized handling requirements, including custom temperature zones, controlled humidity, segregated storage for controlled substances, validated handling protocols for high-potency or cytotoxic materials, and chain-of-custody requirements for clinical trial materials. The right partner conversation begins with your specific requirements, not with their off-the-shelf capabilities.

How Euro-American Worldwide Logistics Supports Life Sciences Manufacturers

Euro-American Worldwide Logistics operates a 45,000 square foot FDA-registered, cGMP-compliant facility in Worcester, Massachusetts. Our 25,000 square feet of validated temperature-controlled storage supports refrigerated (2 to 8°C) and controlled room temperature (15 to 25°C) requirements with continuous 24/7 monitoring, ISO-9001 certified quality systems, and CTPAT-certified security.

What makes our platform distinct is the integration of GMP storage with licensed U.S. Customs Brokerage and international freight forwarding under one roof. For life sciences manufacturers receiving international raw materials, APIs, or finished product, our customs brokerage team handles entry filings while shipments are in transit, with cleared product moving directly into validated storage without a vendor handoff or a gap in the temperature record.

We serve as an extension of our clients’ supply chain operations, with the regulatory infrastructure, validated processes, and integrated logistics capability that make outsourced GMP storage a strategic advantage rather than a contingency.

For questions about GMP storage capacity, customs-integrated receiving, or how outsourced storage might fit your manufacturing operations, contact our team today.